<SEC-DOCUMENT>0001193125-23-170337.txt : 20230621
<SEC-HEADER>0001193125-23-170337.hdr.sgml : 20230621
<ACCEPTANCE-DATETIME>20230620184555
ACCESSION NUMBER:		0001193125-23-170337
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230620
FILED AS OF DATE:		20230621
DATE AS OF CHANGE:		20230620

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		231026914

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d505238d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June&nbsp;20, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d505238dex991.htm">Immutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June&nbsp;20, 2023 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d505238dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g505238g35k76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Granted United States Patent for IMP761, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Class</FONT></FONT> Agonist Antibody Targeting <FONT
STYLE="white-space:nowrap">LAG-3</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 20</B><B></B><B>&nbsp;June </B><B>2023 &#150;</B> <U>Immutep Limited</U> (ASX:
IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,680,104) by the United
States Patent Office. The granted claims are <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">composition-of-matter</FONT></FONT> type claims covering Immutep&#146;s <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
immunosuppressive product candidate IMP761, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> agonist <FONT STYLE="white-space:nowrap">LAG-3</FONT> antibody designed to target the root cause of
autoimmune diseases by directly silencing self-antigen-specific effector T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent is owned by Immutep S.A.S. and will expire on
22&nbsp;February 2037 (including 174 days of patent term adjustment). This new United States patent follows the grant of the equivalent Japanese and European patents announced in July 2022 and October 2020, respectively. A divisional application has
also been filed to pursue claims drawn to methods of treating <FONT STYLE="white-space:nowrap">T-cell</FONT> mediated immune disorders, such as inflammatory or autoimmune diseases, by administration of IMP761. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CSO, Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, said: &#147;We have been making good progress in advancing IMP761 towards potential <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical testing. In particular, we developed a 200L <FONT STYLE="white-space:nowrap">GMP-compliant</FONT> manufacturing process in collaboration with our
colleagues at Northway Biotech late last year, and more recently selected Charles River Laboratories to conduct a GLP toxicology study, a key step prior to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trials. In tandem, we continue to build our patent estate around this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drug candidate in key markets globally.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
IMP761 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive <FONT
STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites. These T cells express <FONT
STYLE="white-space:nowrap">LAG-3</FONT> as an &#147;exhaustion marker&#148; after being repeatedly stimulated with dominant self-peptides. As published in the&nbsp;<U>Journal of Immunology</U>&nbsp;in January 2020, encouraging <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> results were achieved with IMP761 leading to significant inhibition of inflammatory T cell infiltration. Additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> findings published in
<U>Pediatric Research</U>&nbsp;in May 2021 show IMP761 led to large decreases in effector T cell cytokine secretion in a juvenile arthritis model. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g505238g35k76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the CEO of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;33, Australia Square, 264 George
Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g505238g35k76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g505238g35k76.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * #(H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#G_&$\D.AE4)'F2*C8],$_TJ*CM$Y\1)QAH8NA6&
MG:Y>33O;"%8E4>0C_*2<_-Z]JSA%-W,:,857ML)XBDDT6>2VLV"17BEI">6/
M;&3V_P :)^[L*M>D[1ZFUX.N9+C1=KDD12%%/MP?ZUI3=T;8:5X6['0U9TA0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M$?\ Z"* /+_'D*6?BIG@ 0R1K*=O9LD9_2@#UJ)M\*-Z@&@!] !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVD' QUR* .;C6\\;>*C)LV(2-WI'&.V?7^IH ]A4 * !@"@!: "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *;:5I\EQ]H:SA,V
M0V\J,Y]<TN57N1[.+=[$ES9VMXJK<P)*%.0'&<4-)[CE",M)(D@AAMHEAA18
MXUZ*HP!0E;0:2BK(KOI=B]S]I>TB,VX-O*\Y'0TN57N2Z<6[V++QI+$T;J&1
M@00>A%46]58@MM/L[)F:VMHXBPP2BXS222V(C",=D-ETRPGN//EM(GEX.\KD
MTN5 Z<6[M%IU1T*. 5(P0>XJBVKE>VTZQLY"]M:Q1.1@E%P<4E%+8B,(QV0Z
MZL[6\55N8$E53D!QG!H:3W'**EN/@AAMHEBAC6.->BJ, 4)6V'&*BK(KW^EZ
M?J2J+VUBGV_=+#D?0TQE%/"6@(V?[,A./[V6_F: -6VM;:SB\JU@CACSG;&H
M4?I0!7OM(T_4]IO;2*8J, LO(^AZT 06GAS1K&42V^GP)(O*L1DCZ9Z4 :AP
M1@X(H QI_"NA3N7?3( QY.T;?T&* +-CHFF::V^TLH8GQC<J_-^?6@#@?B9_
MR&+/_KA_[,: .MLO#6C7NF64T^G0M(T"$L!MR=HZXH VK.PM-/A\JTMXX$]$
M7&: +'2@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H H6$X:2ZC:0%Q.V%+<@8% %"TO9'U 7$BS)%<L8T#?<P/N$>Y )_P"!
M#TH FBEB#22S2.TZW/E[/-(VY?:ORY]"#0!=E=I(IDDB\L X0M)@/Z<CD4 ,
MTB1I--1F;<P9QG=N'#$<'N/0T 5)C/+I\D<<[Q2M=%5D'5</_+CI0!'!<W$^
MKVLL@DB0H\1B/ + *2<=^<@'T'O0!522^.G2P++-F</,LV"=BY;*@]N@Q[-[
M4 :KW(CU"%I9=D3V[-\S8&<C^AH SH7NI+32#',XE97?!;A\#(#>QH >EY)-
MI\TQ:2*,W85]QPT:Y (]N>/SH MV_E-?RV\,K/#Y8W@2EMIR<8.>,C/Y4 5[
MC?;^'=1FCEF$JK.%8R,2,,V,<\=!0!/%-=?VY''.$13;.0J2%@2&7DY ]: (
M]+=CI7F-(ID, ;<L[.?N]2#T- #=,EF6Y43J\*BW#8:9I!)TRPSTQW_WA0 W
M3[]WOEDE\Y8KT$QB1<*".5 ^J\_A0 ZPCO)IXY@62)9)-[-*6\P98 !>@QP?
MPH LV7G-?S0R2$I:\)\QRV[GGZ#C]: .#^)F!K%G_P!</_9C0!Z%H_\ R!;'
M_K@G_H(H NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0!'Y,0D\P1IO\ [VT9_.@!VQ< ;1@=!CI0 AAB9P[1H7'1BHR*
M %9$=2KJ&7T(R* %5550J@ #H * #:O]T=<].]  5&0<#(Z4  4!=N!CTH :
M\4<BA7C5@.@(SB@!VT9!P..GM0 FQ<$;1@]1CK0 )&D8Q&BH/11B@!2BE2I4
M;3U&* #:,YP,],T ,2"*,DI$BD\$A0* '%%/!4=,=* %*J<94<=..E    ,
M8H   "2  3UH 9)!%*09(D<CNR@T / "@   #@ 4 +0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M_/>/_OH47#GCW#[7;_\ />/_ +Z%%PYX]P^UV_\ SWC_ .^A1<.>/</M=O\
M\]X_^^A1<.>/</M=O_SWC_[Z%%PYX]P^UV__ #WC_P"^A1<.>/</M=O_ ,]X
M_P#OH47#GCW#[7;_ //>/_OH47#GCW#[7;_\]X_^^A1<.>/</M=O_P ]X_\
MOH47#GCW#[7;_P#/>/\ [Z%%PYX]P^UV_P#SWC_[Z%%PYX]P^UV__/>/_OH4
M7#GCW#[7;_\ />/_ +Z%%PYX]P^UV_\ SWC_ .^A1<.>/</M=O\ \]X_^^A1
M<.>/</M=O_SWC_[Z%%PYX]P^UV__ #WC_P"^A1<.>/</M=O_ ,]X_P#OH47#
MGCW#[7;_ //>/_OH47#GCW#[7;_\]X_^^A1<.>/</M=O_P ]X_\ OH47#GCW
M#[7;_P#/>/\ [Z%%PYX]P^UV_P#SWC_[Z%%PYX]P^UV__/>/_OH47#GCW#[7
M;_\ />/_ +Z%%PYX]P^UV_\ SWC_ .^A1<.>/</M=O\ \]X_^^A1<.>/</M=
MO_SWC_[Z%%PYX]P^UV__ #WC_P"^A1<.>/</M=O_ ,]X_P#OH47#GCW#[7;_
M //>/_OH47#GCW#[7;_\]X_^^A1<.>/</M=O_P ]X_\ OH47#GCW#[7;_P#/
M>/\ [Z%%PYX]P^UV_P#SWC_[Z%%PYX]P^UV__/>/_OH47#GCW#[7;_\ />/_
M +Z%%PYX]P^UV_\ SWC_ .^A1<.>/</M=O\ \]X_^^A1<.>/</M=O_SWC_[Z
M%%PYX]P^UV__ #WC_P"^A1<.>/</M=O_ ,]X_P#OH47#GCW#[7;_ //>/_OH
M47#GCW#[7;_\]X_^^A1<.>/</M=O_P ]X_\ OH47#GCW#[7;_P#/>/\ [Z%%
MPYX]P^UV_P#SWC_[Z%%PYX]P^UV__/>/_OH47#GCW#[7;_\ />/_ +Z%%PYX
M]P^UV_\ SWC_ .^A1<.>/</M=O\ \]X_^^A1<.>/</M=O_SWC_[Z%%PYX]P^
MUV__ #WC_P"^A1<.>/</M=O_ ,]X_P#OH47#GCW#[7;_ //>/_OH47#GCW#[
M7;_\]X_^^A1<.>/</M=O_P ]X_\ OH47#GCW#[7;_P#/>/\ [Z%%PYX]P^UV
M_P#SWC_[Z%%PYX]P^UV__/>/_OH47#GCW#[7;_\ />/_ +Z%%PYX]P^UV_\
MSWC_ .^A1<.>/</M=O\ \]X_^^A1<.>/</M=O_SWC_[Z%%PYX]P^UV__ #WC
M_P"^A1<.>/</M=O_ ,]X_P#OH47#GCW#[7;_ //>/_OH47#GCW#[7;_\]X_^
M^A1<.>/</M=O_P ]X_\ OH47#GCW#[7;_P#/>/\ [Z%%PYX]P^UV_P#SWC_[
MZ%%PYX]P^UV__/>/_OH47#GCW#[7;_\ />/_ +Z%%PYX]P^UV_\ SWC_ .^A
M1<.>/</M=O\ \]X_^^A1<.>/</M=O_SWC_[Z%%PYX]P^UV__ #WC_P"^A1<.
M>/</M=O_ ,]X_P#OH47#GCW#[7;_ //>/_OH47#GCW#[7;_\]X_^^A1<.>/<
M/M=O_P ]X_\ OH47#GCW#[7;_P#/>/\ [Z%%PYX]P^UV_P#SWC_[Z%%PYX]P
M^UV__/>/_OH47#GCW$^UV_\ SWC_ .^A1=!S1[GG?_"*:S_SYC_OM?\ &L.2
M1YOL*O8/^$4UG_GS'_?:_P"-')(/85>P?\(IK/\ SYC_ +[7_&CDD'L*O8/^
M$4UG_GS'_?:_XT<D@]A5[!_PBFL_\^8_[[7_ !HY)!["KV#_ (136?\ GS'_
M 'VO^-')(/85>P?\(IK/_/F/^^U_QHY)!["KV#_A%-9_Y\Q_WVO^-')(/85>
MP?\ "*:S_P ^8_[[7_&CDD'L*O8/^$4UG_GS'_?:_P"-')(/85>P?\(IK/\
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MP?\ "*:S_P ^8_[[7_&CDD'L*O8/^$4UG_GS'_?:_P"-')(/85>P?\(IK/\
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MP?\ "*:S_P ^8_[[7_&CDD'L*O8/^$4UG_GS'_?:_P"-')(/85>P?\(IK/\
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MP?\ "*:S_P ^8_[[7_&CDD'L*O8/^$4UG_GS'_?:_P"-')(/85>P?\(IK/\
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
